Binimetinib

Drug Profile

Binimetinib

Alternative Names: ARRY-162; ARRY-438162; MEK-162; Mitogen activated kinase inhibitor

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Array BioPharma; Dana-Farber Cancer Institute
  • Developer Array BioPharma; German Cancer Research Center; Merck KGaA; Novartis; Pierre Fabre; Seoul National University Hospital; University of Heidelberg
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Haematological malignancies; Multiple myeloma; Neurofibromatoses; Non-small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Biliary cancer; Chronic myeloid leukaemia; Pancreatic cancer
  • Discontinued Rheumatoid arthritis; Uveal melanoma

Most Recent Events

  • 19 Mar 2017 Regulatory submission withdrawn for Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)
  • 09 Mar 2017 Array BioPharma terminates a phase I trial in Healthy volunteers and subjects with hepatic impairment in USA prior to March 2017 due to achievement of the primary objective on assessment of five of six subjects in the final cohort (NCT02050815)
  • 15 Feb 2017 University of Utah re-initiates enrolment in a phase-I trial in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT02613650)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top